Trials / Approved For Marketing
Approved For MarketingNCT01995734
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy (ACCESS)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide LAR while regulatory approval for pasireotide is sought.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasireotide long acting release formulation | Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first. |
Timeline
- First posted
- 2013-11-27
- Last updated
- 2015-12-29
Locations
37 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01995734. Inclusion in this directory is not an endorsement.